INMED PHARMACEUTICALS INC (INM)

Company Profile

InMed Pharmaceuticals Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. InMed Pharmaceuticals Inc. is a pharmaceutical company. The company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

Company Info

INMED PHARMACEUTICALS INC

1445-885 West Georgia St.

Vancouver BRITISH COLUMBIA V6C1B4

P: 16046697207

CEO: Eric Adams

Employees: 13

Website: https://www.inmedpharma.com/